Filtered By:
Condition: Diabetes
Management: Funding
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 117 results found since Jan 2013.
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Depression Is More than a Stigma
Manoj K. Pandey is Lecturer in Economics, Australian National University; Vani S. Kulkarni is Lecturer in Sociology, University of Pennsylvania; and Raghav Gaiha is (Hon. ) Professorial Research Fellow, Global Development Institute, University of ManchesterBy Manoj K. Pandey, Vani S. Kulkarni and Raghav GaihaCanberra, Philadelphia and Manchester, Mar 20 2019 (IPS) Depression is often distinguished from other non-communicable diseases or NCDs (e.g., cancer, diabetes, cardio-vascular diseases, hypertension) because of the stigma attached to it. Among other consequences, those suffering from depression are often denied access...
Source: IPS Inter Press Service - Health - March 20, 2019 Category: International Medicine & Public Health Authors: Manoj K. Pandey - and Raghav Gaiha Tags: Featured Global Headlines Health Human Rights TerraViva United Nations Women's Health Source Type: news
Plasma epoxyeicosatrienoic acids and diabetes-related cardiovascular disease: The cardiovascular health study
EBioMedicine. 2022 Aug 2;83:104189. doi: 10.1016/j.ebiom.2022.104189. Online ahead of print.ABSTRACTBACKGROUND: Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid that may impact atherosclerosis, and animal experimental studies suggest EETs protect cardiac function. Plasma EETs are mostly esterified to phospholipids and part of an active pool. To address the limited information about EETs and CVD in humans, we conducted a prospective study of total plasma EETs (free + esterified) and diabetes-related CVD in the Cardiovascular Health Study (CHS).METHODS: We measured 4 EET species and their metabolites, dih...
Source: Atherosclerosis - August 5, 2022 Category: Cardiology Authors: Rozenn N Lemaitre Paul N Jensen Maxwell Zeigler Amanda M Fretts Jason G Umans Barbara V Howard Colleen M Sitlani Barbara McKnight Sina A Gharib Irena B King David S Siscovick Bruce M Psaty Nona Sotoodehnia Rheem A Totah Source Type: research
Stem Cells for Cell-Based Therapies
The world of stem cells
We know the human body comprises many cell types (e.g., blood cells, skin cells, cervical cells), but we often forget to appreciate that all of these different cell types arose from a single cell—the fertilized egg. A host of sequential, awe-inspiring events occur between the fertilization of an egg and the formation of a new individual:
Embryonic stem (ES) cells are also called totipotent cells.
The first steps involve making more cells by simple cell division: one cell becomes two cells; two cells become four cells, etc.
Each cell of early development is undifferentiated; that is, it is...
Source: ActionBioscience - December 28, 2012 Category: Science Authors: Ali Hochberg Source Type: news
Why You Should Avoid Statins
At my anti-aging clinic, I continue to wage war against what I call the “medical-industrial complex.”
And I do it for one reason only – I care more about my patients than I do about profits.
Big Pharma clearly takes the opposite view. And now it seems these pharmaceutical behemoths won’t be happy until every man, woman and child is popping anti-cholesterol pills.
Researchers at Duke University recently issued a report recommending that even children and people as young as 30 should be on statins, if they have just slightly elevated cholesterol levels.1
And why wouldn’t researchers at Duke recommen...
Source: Al Sears, MD Natural Remedies - February 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Heart Health Source Type: news
Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis
Publication date: Available online 6 February 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Rachel R Huxley , Sanne A E Peters , Gita D Mishra , Mark Woodward Background Studies have suggested sex differences in the mortality rate associated with type 1 diabetes. We did a meta-analysis to provide reliable estimates of any sex differences in the effect of type 1 diabetes on risk of all-cause mortality and cause-specific outcomes. Methods We systematically searched PubMed for studies published between Jan 1, 1966, and Nov 26, 2014. Selected studies reported sex-specific estimates of the standardised m...
Source: The Lancet Diabetes and Endocrinology - February 6, 2015 Category: Endocrinology Source Type: research
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis
Publication date: Available online 26 February 2015 Source:The Lancet Diabetes & Endocrinology Background To investigate potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition, we studied genetic variants that produce inhibition of IL-1, a master regulator of inflammation. Methods We created a genetic score combining the effects of alleles of two common variants (rs6743376 and rs1542176) that are located upstream of IL1RN, the gene encoding the IL-1 receptor antagonist (IL-1Ra; an endogenous inhibitor of both IL-1α and IL-1β); both alleles increase soluble IL-1Ra ...
Source: The Lancet Diabetes and Endocrinology - February 26, 2015 Category: Endocrinology Source Type: research
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study
This study suggests that measurement of grip strength is a simple, inexpensive risk-stratifying method for all-cause death, cardiovascular death, and cardiovascular disease. Further research is needed to identify determinants of muscular strength and to test whether improvement in strength reduces mortality and cardiovascular disease. Funding Full funding sources listed at end of paper (see Acknowledgments).
Source: The Lancet - May 15, 2015 Category: Journals (General) Source Type: research
Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
Publication date: Available online 28 May 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Kunihiro Matsushita , Josef Coresh , Yingying Sang , John Chalmers , Caroline Fox , Eliseo Guallar , Tazeen Jafar , Simerjot K Jassal , Gijs W D Landman , Paul Muntner , Paul Roderick , Toshimi Sairenchi , Ben Schöttker , Anoop Shankar , Michael Shlipak , Marcello Tonelli , Jonathan Townend , Arjan van Zuilen , Kazumasa Yamagishi , Kentaro Yamashita , Ron Gansevoort , Mark Sarnak , David G Warnock , Mark Woodward , Johan Ärnlöv Background The usefulness of estimated glomerular filtration rate (eGFR) and albumin...
Source: The Lancet Diabetes and Endocrinology - May 30, 2015 Category: Endocrinology Source Type: research
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Publication date: Available online 7 November 2015 Source:The Lancet Author(s): Xinfang Xie, Emily Atkins, Jicheng Lv, Alexander Bennett, Bruce Neal, Toshiharu Ninomiya, Mark Woodward, Stephen MacMahon, Fiona Turnbull, Graham S Hillis, John Chalmers, Jonathan Mant, Abdul Salam, Kazem Rahimi, Vlado Perkovic, Anthony Rodgers Background Recent hypertension guidelines have reversed previous recommendations for lower blood pressure targets in high-risk patients, such as those with cardiovascular disease, renal disease, or diabetes. This change represents uncertainty about whether more intensive blood pressure-...
Source: The Lancet - November 9, 2015 Category: Journals (General) Source Type: research
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Publication date: Available online 18 March 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We a...
Source: The Lancet Diabetes and Endocrinology - March 19, 2016 Category: Endocrinology Source Type: research
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Publication date: Available online 29 July 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Cholesterol Treatment Trialists' (CTT) Collaboration Background Statin therapy is effective for the prevention of coronary heart disease and stroke in patients with mild-to-moderate chronic kidney disease, but its effects in individuals with more advanced disease, particularly those undergoing dialysis, are uncertain. Methods We did a meta-analysis of individual participant data from 28 trials (n=183 419), examining effects of statin-based therapy on major vascular events (major coronary event [non-fatal myoca...
Source: The Lancet Diabetes and Endocrinology - July 28, 2016 Category: Endocrinology Source Type: research
Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
Publication date: Available online 10 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Sanjay Basu, Jeremy B Sussman, Seth A Berkowitz, Rodney A Hayward, John S Yudkin Background In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe). Methods To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001–09) and validated the equations for microvascular events using data from the Di...
Source: The Lancet Diabetes and Endocrinology - August 11, 2017 Category: Endocrinology Source Type: research
